01—Abstract
Summary
Summary of the 8-K filed October 7, 2024. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024.
The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 milliona on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter.
Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.
02—Key points
Key Highlights
- Regeneron expects a pre-tax IPR&D charge of approximately $56 million for Q3 2024.
- This charge is attributed to milestone and up-front payments for collaboration and licensing agreements.
- The IPR&D charge is estimated to decrease Q3 2024 GAAP and non-GAAP net income per diluted share by approximately $0.43.
- The reported figures are preliminary estimates and subject to finalization of financial closing procedures.
- Acquired IPR&D charges are not typically forecasted by Regeneron due to their unpredictable nature.
- The company provided a cautionary note regarding forward-looking statements and potential material differences in actual results.
03—Questions
Frequently Asked Questions
What is the primary financial impact disclosed in this 8-K filing?
The primary financial impact disclosed is an expected acquired in-process research and development (IPR&D) charge of approximately $56 million (pre-tax) for the third quarter of 2024, which is anticipated to reduce net income per diluted share by $0.43 on both GAAP and non-GAAP bases.
What causes this IPR&D charge?
The charge is a result of development milestone and up-front payments made in connection with collaboration and licensing agreements.
Are these Q3 2024 results finalized?
No, the results are not finalized. Regeneron states that the figures are preliminary estimates and are subject to the company's financial statement closing procedures. Actual results may differ.
Why does Regeneron not forecast IPR&D charges?
Regeneron does not forecast acquired IPR&D charges because the future occurrence, magnitude, and timing of these transactions are uncertain, making them difficult to predict accurately.
04—Continue